EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtVergleichsstudie

Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials

Wania Ahmer, Sahar Imtiaz, Daniyal Muhammad Alam, Khadija Ahmed, Barka Sajid, Juvairia Yousuf, Sunny Asnani, Muhammad Ahmed Ali Fahim, Rahmeen Ali, Marium Mansoor, Muhammad Talha Safdar, Muhammad Umair Anjum und 2 weitere

European Journal of Clinical Pharmacology · 2024-04 · 80 (4) · 493-503

DOI: 10.1007/s00228-024-03624-6 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 23.01.2024. Verfasst von Wania Ahmer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow Medical College, Karachi, Pakistan. Hauptthemen laut MEDLINE: Propofol, Colonoscopy, Hypnotics and Sedatives, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Propofol has become the sedative of choice for endoscopy and colonoscopy. However, it has shown associations with various adverse effects, specifically in the geriatric population. In contrast, remimazolam is a novel benzodiazepine, demonstrating a superior clinical safety profile. Hence, this systematic review and meta-analysis aims to clarify the efficacy and safety of remimazolam versus propofol in elderly patients (≥ 60 years) undergoing gastrointestinal endoscopic and colonoscopy procedures. METHODS: Electronic databases including PubMed, Cochrane Library, ScienceDirect, and Google Scholar were explored from inception till January 7, 2024. The Cochrane Risk of Bias Tool for Randomized Controlled Trials (RoB-2) was utilized to evaluate the quality of each included study reported in this meta-analysis. RESULTS: Seven randomized control trials were included, resulting in the pooling of 1,466 patients (remimazolam: 731 patients; propofol: 735 patients). Propofol demonstrated a significantly lower time to loss of consciousness (P < 0.00001, 4 studies, 784 patients) and a greater sedation success after first dose (P = 0.05, 5 studies, 1,271 patients). Remimazolam reported a significantly lower risk of bradycardia (P = 0.02, 5 studies, 1,323 patients), hypoxemia (P < 0.00001, 6 studies, 1,389 patients), and pain on injection site (P < 0.00001, 5 studies, 1,184 patients). No statistically significant differences in sedation time, number of supplemental doses, procedural parameters, and other adverse outcomes were reported. CONCLUSION: As per the results of our analyses, propofol demonstrated comparatively superior efficacy, however, remimazolam demonstrated comparatively superior safety. The debatable evidence generated from this meta-analysis may not currently be powerful enough to advocate for the use of remimazolam in elderly patients undergoing gastrointestinal procedures; hence, further comprehensive studies are necessary in order to arrive at a robust conclusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropofolColonoscopyHypnotics and SedativesRandomized Controlled Trials as TopicBenzodiazepinesEndoscopy, GastrointestinalHumansAgedMiddle Aged

Stichwörter der Autor:innen

ColonoscopyElderlyEndoscopyMeta-analysisPropofolRemimazolam

Substanzen

remimazolamPropofolHypnotics and SedativesBenzodiazepines

Autor:innen und Institutionen

  • Department of Medicine, Dow Medical College, Karachi, Pakistan.
  • Department of Medicine, Dow International Medical College, Karachi, Pakistan.
  • Department of Medicine, Sindh Medical College, Karachi, Pakistan.
  • Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
  • Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan.
  • Department of Medicine, Dow International Medical College, Karachi, Pakistan. omarlarik@gmail.com.

Zitieren

APA

Ahmer, W., Imtiaz, S., Alam, D. M., Ahmed, K., Sajid, B., Yousuf, J., Asnani, S., Fahim, M. A. A., Ali, R., Mansoor, M., Safdar, M. T., Anjum, M. U., Hasanain, M., & Larik, M. O. (2024). Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 80(4), 493-503. https://doi.org/10.1007/s00228-024-03624-6

Vancouver

Ahmer W, Imtiaz S, Alam DM, Ahmed K, Sajid B, Yousuf J, et al. Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology. 2024;80(4):493-503. doi:10.1007/s00228-024-03624-6

BibTeX
@article{Ahmer2024,
  author = {Ahmer, Wania and Imtiaz, Sahar and Alam, Daniyal Muhammad and Ahmed, Khadija and Sajid, Barka and Yousuf, Juvairia and Asnani, Sunny and Fahim, Muhammad Ahmed Ali and Ali, Rahmeen and Mansoor, Marium and Safdar, Muhammad Talha and Anjum, Muhammad Umair and Hasanain, Muhammad and Larik, Muhammad Omar},
  title = {Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials},
  journal = {European Journal of Clinical Pharmacology},
  year = {2024},
  volume = {80},
  number = {4},
  pages = {493--503},
  doi = {10.1007/s00228-024-03624-6}
}
Kostenlos starten →